Table 2.
Indications for warfarin treatment in the cohorts treated with either FEIBA or FFP
| Indication | FEIBA n = 72 | FFP n = 69 | ||||
|---|---|---|---|---|---|---|
| INR <5 | INR ≥5 | total | INR <5 | INR ≥5 | Total | |
| Atrial fibrillation | 61.2%(30) | 34.8%(8) | 52.8%(38) | 38.9%(21) | 33.3%(5) | 37.7%(26) |
| Complicated atrial fibrillation | 6.1%(3) | 8.7%(2) | 6.9%(5) | 14.8%(8) | 13.3%(2) | 14.5%(10) |
| Atherosclerosis | 6.1%(3) | 21.7%(5) | 11.1%(8) | 1.2%(1) | 20.0%(3) | 5.8%(4) |
| Valve replacement | 12.2%(6) | 8.7%(2) | 11.1%(8) | 14.8%(8) | 6.7%(1) | 13.0%(9) |
| Thromboembolism | 10.2%(5) | 21.8%(5) | 13.9%(10) | 24.1%(13) | 26.7%(4) | 24.6%(17) |
| Other | 4.1%(2) | 4.3%(1) | 4.2%(3) | 5.6%(3) | 0.0%(0) | 4.3%(3) |
| Total | 100%(49) | 100%(23) | 100%(72) | 100%(54) | 100%(15) | 100%(69) |
P = 0.511 using chi-square with 5 degrees of freedom comparing the FEIBA group with the FFP group subdivided by indications